TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress

NEXT STORY
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19
PREV STORY
Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

The Tower Companies Installs Cutting Edge Far-UVC 222 Light Sanitizing Technology at The Millennium Building

author_avatar
NASDAQ Market News

GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19

author_avatar
NASDAQ Market News

Cancer Genetics, Inc. Launches Next Generation Sequencing Panel for Diagnosis & Treatment Selection in Solid Tumors, CGI FOCUS::Oncomine™

CGI has launched the next-generation sequencing (NGS) panel with CLIA validation and will perform ...

author_avatar
NASDAQ Market News